TScan Therapeutics, Inc. SEC filings TCRX
TScan Therapeutics, Inc. has 334 filings in SEC EDGAR's recent list, going back to Jul 26, 2019. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 14, 2025 | — |
| CORRESP | Letter to the SEC | Mar 12, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| EFFECT | Filing | Apr 12, 2024 | — |
| CORRESP | Letter to the SEC | Apr 10, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 7, 2024 | — |
| EFFECT | Filing | May 16, 2023 | — |
| EFFECT | Filing | May 16, 2023 | — |
| AW | Filing | May 16, 2023 | — |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| CORRESP | Letter to the SEC | May 10, 2023 | — |
| CORRESP | Letter to the SEC | May 10, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2022 | — |
| EFFECT | Filing | Jul 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jul 15, 2021 | — |
| CERT | Filing | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 14, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 13, 2021 | — |
| 8-A12B | Filing | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | May 5, 2021 | — |
| UPLOAD | Letter from the SEC | May 3, 2021 | — |
| CORRESP | Letter to the SEC | Apr 30, 2021 | — |
| CORRESP | Letter to the SEC | Apr 30, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 28, 2021 | — |
| CORRESP | Letter to the SEC | Apr 23, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 12, 2021 | — |
| DRS | Filing | Mar 19, 2021 | — |
| D | Filing | Jan 28, 2021 | — |
| D | Filing | Jul 26, 2019 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1783328
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.